First-Generation Radiolabeled Cyclic Peptides for Molecular Imaging of Platelet-Derived Growth Factor Receptor α
Molecular Pharmaceutics · 2024
DOI: 10.1021/acs.molpharmaceut.4c00549 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Susan Pike und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, University of Alberta, Edmonton, Canada T6G 1Z2. Hauptthemen laut MEDLINE: Peptides, Cyclic, Receptor, Platelet-Derived Growth Factor alpha, Gallium Radioisotopes, Molecular Imaging. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Dianne and Irving Kipnes Foundation.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, University of Alberta, Edmonton, Canada T6G 1Z2.
- Department of Surgery, University of Alberta, Edmonton, Canada T6G 2B7.
- Department of Chemistry, University of Alberta, Edmonton, Canada T6G 2N4.
ORCID-Profile: Ratmir Derda, Frank Wuest
Förderung
- Dianne and Irving Kipnes Foundation
Zitieren
APA
Pike, S., Wuest, M., Lopez-Campistrous, A., Hu, M. Y., Derda, R., Wuest, F., & McMullen, T. (2024). First-Generation Radiolabeled Cyclic Peptides for Molecular Imaging of Platelet-Derived Growth Factor Receptor α. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00549
Vancouver
Pike S, Wuest M, Lopez-Campistrous A, Hu MY, Derda R, Wuest F, et al. First-Generation Radiolabeled Cyclic Peptides for Molecular Imaging of Platelet-Derived Growth Factor Receptor α. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00549
BibTeX
@article{Pike2024,
author = {Pike, Susan and Wuest, Melinda and Lopez-Campistrous, Ana and Hu, Mi Yao and Derda, Ratmir and Wuest, Frank and McMullen, Todd},
title = {First-Generation Radiolabeled Cyclic Peptides for Molecular Imaging of Platelet-Derived Growth Factor Receptor α},
journal = {Molecular Pharmaceutics},
year = {2024},
doi = {10.1021/acs.molpharmaceut.4c00549}
}
EUVIMED